Published in
Wiley, Diabetes, Obesity and Metabolism, 9(24), p. 1840-1849, 2022
DOI: 10.1111/dom.14770
Links
Tools
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial
Journal article published in 2022 by
Lorenzo Piemonti 
,
Bart Keymeulen ,
Pieter Gillard ,
Thomas Linn,
Emanuele Bosi ,
Ludger Rose,
Paolo Pozzilli ,
Francesco Giorgino ,
Efisio Cossu,
Luisa Daffonchio,
Giovanni Goisis,
Pier Adelchi Ruffini,
Anna Rita Maurizi,
Flavio Mantelli,
Marcello Allegretti
,
Bart Keymeulen ,
Pieter Gillard ,
Thomas Linn,
Emanuele Bosi ,
Ludger Rose,
Paolo Pozzilli ,
Francesco Giorgino ,
Efisio Cossu,
Luisa Daffonchio,
Giovanni Goisis,
Pier Adelchi Ruffini,
Anna Rita Maurizi,
Flavio Mantelli,
Marcello Allegretti
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 